Metfogamma (Metformin Hydrochloride)

Metfogamma, a biguanide antidiabetic, is used to improve glycemic control in disorders related to insulin resistance.

• Type 2 diabetes mellitus: improves blood glucose control and reduces HbA1c levels.
• Impaired glucose tolerance: helps normalize fasting glucose and delay progression to diabetes.
• Metabolic syndrome: contributes to weight management and enhances insulin sensitivity.

• Metformin Hydrochloride acts primarily by inhibiting hepatic gluconeogenesis, thereby decreasing endogenous glucose production. It also enhances peripheral glucose uptake by increasing insulin‑stimulated translocation of GLUT‑4 transporters in muscle and adipose tissue, and modestly reduces intestinal absorption of glucose. The drug does not bind to a specific receptor but influences AMP‑activated protein kinase (AMPK) pathways, which further contributes to its metabolic effects.

Metfogamma may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Nausea: transient feeling of sickness, often early in therapy.
• Diarrhea: loose stools that may improve with dose adjustment.
• Abdominal discomfort: cramping or pain in the stomach area.
• Metallic taste: unusual taste sensation in the mouth.

Serious or Rare Side Effects

• Lactic acidosis: rare but life‑threatening buildup of lactate, requiring immediate medical attention.
• Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Hepatic dysfunction: signs of liver injury including jaundice or elevated enzymes.
• Vitamin B12 deficiency: long‑term use may reduce B12 absorption leading to anemia.

When prescribing Metfogamma, clinicians should consider several safety measures to minimize risk.

• Renal function: assess eGFR before initiation and monitor periodically.
• Hepatic function: avoid use in patients with severe liver disease.
• Lactic acidosis risk: discontinue if patient develops unexplained fatigue, dyspnea, or abdominal pain.
• Pregnancy: use only if potential benefit justifies potential fetal risk.
• Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Metfogamma can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Iodinated contrast agents: may precipitate lactic acidosis; suspend metformin before and after imaging.
• Cimetidine: can increase metformin plasma concentrations.
• Alcohol excess: heightens risk of lactic acidosis.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may mask hypoglycemia symptoms.
• Diuretics: can affect renal clearance of metformin.
• Corticosteroids: may raise blood glucose, requiring dose adjustment.
• Thyroid hormones: may influence metabolic rate and glucose control.